JC virus granule cell neuronopathy
Citation, DOI & article data
JC virus granule cell neuronopathy results from the reactivation of the John Cunningham virus (JC virus), infecting granule cell neurons in the cerebellum, in patients with compromised immune systems.
immunosuppression is the most significant risk factor 1-3,5,7:
- immunosuppressive monoclonal antibody therapy (e.g. rituximab, natalizumab)
- congenital CD40 ligand deficiency
- lymphoma with chronic leukopenia
Patients present with progressive subacute or chronic cerebellar and brainstem dysfunction, characterized by signs and symptoms such as 2,3:
- gait disturbance
JC virus granule cell neuronopathy is secondary to progressive infection of granule cell neurons in the cerebellum due to the reactivation of the JC virus 1-4. It has been postulated that for the JC virus to preferentially infect granule cell neurons instead of glial cells, there must be a mutation, typically involving the C terminus of the VP1 gene, that triggers this change 6.
There is derangement of the normal laminar cellular organization of cerebellum, with the hallmark histological feature of JC virus granule cell neuronopathy being infection and loss of granule cell neurons in the internal granule cell layer, with sparing of the molecular and Perkinje layers 1,3. Additionally, there may also be involvement of nearby glial cells (e.g. oligodendrocytes and astrocytes) 1.
The most characteristic finding is bilateral, diffuse, symmetric cerebellar atrophy 1-3. This is seen in almost all cases reported in the literature 1.
In addition to this, there may be associated infratentorial white matter changes noted in the cerebellum and brainstem, with a particular predilection for the pons and middle cerebellar peduncles 1,2:
- T1: normal
T2/FLAIR: confluent hyperintense regions
- a hot cross bun sign may be noted if the pons is involved
- T1 C+ (Gd): no enhancement
There is conjecture whether these white matter changes are truly due to JC virus granule cell neuronopathy, or due to concurrent infratentorial progressive multifocal leukoencephalopathy 1-3. Regardless, supratentorial white matter involvement, on the other hand, is not a feature of JC virus granule cell neuronopathy, and its involvement may be due to other manifestations of the JC virus such as progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome, which are known to manifest concurrently with JC virus granule cell neuronopathy 1-3.
One case report describes use of FDG-PET to aid in the diagnosis, showing patchy hypometabolism in the cerebellum, reflective of neuronal cell loss 7.
Treatment and prognosis
There is currently (as of March 2019) no disease-specific therapy available for JC virus granule cell neuronopathy, and management is therefore supportive.
Longitudinal prognostic data is lacking in the literature; however, small case series suggest that patients will often have a progressive course that will eventually plateau over months with persisting neurological disability 2.
- 1. Wijburg MT, van Oosten BW, Murk JL, Karimi O, Killestein J, Wattjes MP. Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature. (2015) Journal of neurology. 262 (1): 65-73. doi:10.1007/s00415-014-7530-5 - Pubmed
- 2. Henry C, Jouan F, De Broucker T. JC virus granule cell neuronopathy: A cause of infectious cerebellar degeneration. (2015) Journal of the neurological sciences. 354 (1-2): 86-90. doi:10.1016/j.jns.2015.05.003 - Pubmed
- 3. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. (2010) The Lancet. Neurology. 9 (4): 425-37. doi:10.1016/S1474-4422(10)70040-5 - Pubmed
- 4. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. (2010) Nature reviews. Neurology. 6 (12): 667-79. doi:10.1038/nrneurol.2010.164 - Pubmed
- 5. Demas A, Bennani O, Vandendriessche A, de Menibus LH, Langlois V, Gasnault J. JC Virus Granule Cell Neuronopathy and Lymphoma. (2018) Open forum infectious diseases. 5 (6): ofy112. doi:10.1093/ofid/ofy112 - Pubmed
- 6. Dang L, Dang X, Koralnik IJ, Todd PK. JC polyomavirus granule cell neuronopathy in a patient treated with rituximab. (2014) JAMA neurology. 71 (4): 487-9. doi:10.1001/jamaneurol.2013.4668 - Pubmed
- 7. Kamourieh S, Gananandan K, Raffel J, Nicholas R. Natalizumab granule cell neuronopathy: FDG-PET in diagnosis and immune reconstitution with G-CSF. (2017) Neurology(R) neuroimmunology & neuroinflammation. 4 (5): e384. doi:10.1212/NXI.0000000000000384 - Pubmed